134 related articles for article (PubMed ID: 34858733)
1. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F; Niederer R; Luimstra JJ; Pop OT; Jochum AK; Purde MT; Hasan Ali O; Bomze D; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Dubbelaar ML; Abdou MT; Baumgaertner P; Appenzeller C; Cicin-Sain C; Lenz T; Speiser DE; Ludewig B; Driessen C; Jörger M; Früh M; Jochum W; Cozzio A; Rammensee HG; Walz J; Neefjes J; Flatz L
Oncoimmunology; 2021; 10(1):2006893. PubMed ID: 34858733
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
4. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F; Bomze D; Lichtensteiger C; Walter V; Niederer R; Hasan Ali O; Wyss N; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Abdou MT; Diem S; Knöpfli S; Sinnberg T; Hofmeister K; Cheng HW; Toma M; Klümper N; Purde MT; Pop OT; Jochum AK; Pascolo S; Joerger M; Früh M; Jochum W; Rammensee HG; Läubli H; Hölzel M; Neefjes J; Walz J; Flatz L
Sci Immunol; 2022 Sep; 7(75):eabn9644. PubMed ID: 36054337
[TBL] [Abstract][Full Text] [Related]
5. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
7. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
[TBL] [Abstract][Full Text] [Related]
8. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
[TBL] [Abstract][Full Text] [Related]
11. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
13. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
18. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]